Brokers Issue Forecasts for ERNA Q1 Earnings

Ernexa Therapeutics Inc. (NASDAQ:ERNA) – Research analysts at Brookline Capital Markets issued their Q1 2026 earnings per share estimates for Ernexa Therapeutics in a report issued on Thursday, May 7th. Brookline Capital Markets analyst K. Raja anticipates that the company will post earnings per share of ($1.95) for the quarter. Brookline Capital Markets has a “Buy” rating and a $30.00 price target on the stock. Brookline Capital Markets also issued estimates for Ernexa Therapeutics’ Q2 2026 earnings at ($2.11) EPS, Q3 2026 earnings at ($2.40) EPS, Q4 2026 earnings at ($2.89) EPS, FY2026 earnings at ($9.38) EPS, FY2027 earnings at ($1.18) EPS, FY2028 earnings at ($0.92) EPS, FY2029 earnings at ($1.04) EPS and FY2030 earnings at ($1.17) EPS.

ERNA has been the subject of several other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen upgraded Ernexa Therapeutics to a “hold” rating in a research note on Saturday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $30.00.

Ernexa Therapeutics Stock Down 4.2%

Shares of NASDAQ:ERNA opened at $7.21 on Tuesday. Ernexa Therapeutics has a 12-month low of $3.18 and a 12-month high of $100.46. The stock has a market cap of $8.44 million, a PE ratio of -0.10 and a beta of 1.88. The business has a 50 day moving average of $5.89 and a 200-day moving average of $20.80.

Ernexa Therapeutics (NASDAQ:ERNA) last issued its quarterly earnings data on Monday, May 11th. The company reported ($6.95) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new stake in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 70.55% of the company’s stock.

Trending Headlines about Ernexa Therapeutics

Here are the key news stories impacting Ernexa Therapeutics this week:

• Positive Sentiment: Brookline Capital Markets reiterated a Buy rating on Ernexa Therapeutics and kept a $30 price target, suggesting significant upside from current levels. Brookline Capital Markets estimate report
• Neutral Sentiment: The firm also published detailed EPS estimates for 2026-2030, including expected losses of ($9.38) in FY2026 and smaller losses in later years, which mainly provides forward guidance rather than a new operational catalyst. Analyst forecast update
• Negative Sentiment: Ernexa reported quarterly EPS of ($6.95), which missed consensus estimates of ($1.95) by $5.00, a large earnings shortfall that likely explains why the stock has been under pressure. Earnings miss
• Neutral Sentiment: The company also released a virtual investor segment on its ovarian cancer program and lead candidate ERNA-101, but this looks more informational than immediately market-moving. Investor presentation

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.